Douglass H O, Lavin P T, Evans J T, Mittelman A, Carbone P P
Cancer Treat Rep. 1979 Aug;63(8):1355-7.
The Eastern Cooperative Oncology Group assessed the activity of diglycoaldehyde (DGA), VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with advanced colorectal cancer. Objective responses were seen in two of 40 evaluable patients receiving methyl-CCNU and beta-2'-deoxythioguanosine and in one of 35 patients receiving DGA. None of 33 patients responded to VP-16-213, but one death related to sepsis and bone marrow failure occurred. Survival of patients whose previous chemotherapy included a nitrosourea was markedly shortened compared to those who had not been exposed to nitrosoureas. With the possible exception of DGA, further treatment of patients with colorectal cancer with these therapies is not warranted.
东部肿瘤协作组评估了双甘醇醛（DGA）、依托泊苷（VP-16-213）以及甲环亚硝脲和β-2'-脱氧硫代鸟苷联合用药对先前接受过治疗的晚期结直肠癌患者的疗效。在40例可评估的接受甲环亚硝脲和β-2'-脱氧硫代鸟苷治疗的患者中有2例出现客观缓解，在35例接受DGA治疗的患者中有1例出现客观缓解。33例接受VP-16-213治疗的患者均无反应，但发生了1例与败血症和骨髓衰竭相关的死亡。与未接触过亚硝脲类药物的患者相比，先前化疗中包含亚硝脲类药物的患者生存期明显缩短。除了DGA可能是个例外，这些疗法不适合对结直肠癌患者进行进一步治疗。
